Last updated: May 30, 2026
Saxagliptin Hydrochloride Suppliers (API and Finished-Dose): Who Makes It and What to Source
Saxagliptin hydrochloride is supplied through two practical channels: (1) API manufacturers that produce saxagliptin hydrochloride for global generics and branded brands, and (2) finished-dosage manufacturers that buy API and formulate tablets. The supplier set varies by geography, DMF status, and regulatory history (FDA/EMA).
Key sourcing reality: saxagliptin hydrochloride is not a commodity like some high-volume APIs. Many buyers qualify DMF-backed plants, and supply is concentrated among a smaller group of API makers and their contract manufacturing networks.
Who supplies saxagliptin hydrochloride API for generic manufacturers?
Featured snippet answer: Saxagliptin hydrochloride API supply is concentrated among established India-based and China-based API producers that file FDA Drug Master Files (DMFs) or support abbreviated filings through cross-referenced dossiers for downstream tableting.
API supplier archetypes used in saxagliptin supply chains
- DMF-backed API producers: Offer saxagliptin hydrochloride with validated polymorph/impurity control tied to DMF references.
- Intermediates-led manufacturers: Build from key intermediates (process chemistry suppliers) and finalize saxagliptin HCl as the API.
- Affiliate or contract manufacturers: API is produced under corporate group, then sold through trading arms that handle regulatory documentation and batch release.
How buyers typically qualify a saxagliptin HCl supplier
- Regulatory alignment: DMF letter of authorization structure and FDA filing history.
- Specifications and analytical package: assay range, chiral purity (as relevant), water content, residual solvents.
- Impurity profile: control strategy for process impurities and degradation products.
- Batch reproducibility: CoA traceability and stability program linkage.
- Supply continuity: dedicated production runs versus shared lines for the DPP-4 inhibitor class.
Which companies manufacture saxagliptin hydrochloride tablets in the US market?
Featured snippet answer: US finished-dosage saxagliptin tablets are produced by FDA-registered manufacturers that buy qualified saxagliptin HCl API and formulate to label conditions (strengths and release specifications vary by NDA/ANDA product).
What to check when selecting a tablet supplier
- ANDA vs branded supply: Branded supply often uses a tightly controlled API source, while generics rely on DMF-supported API lots.
- Site-specific approvals: CMC sections can lock to specific manufacturing sites.
- Blend strategy and dissolution targets: Tablet suppliers frequently differ in excipient systems, which impacts bioequivalence performance.
Is saxagliptin hydrochloride supplied by US or EU API makers only, or is it mostly imported?
Featured snippet answer: Supply is predominantly global with cross-border sourcing, with many buyers importing API and manufacturing finished dosage either in the US via contract sites or through international CDMOs.
Common trade pattern
- API: Asia-based producers supply global demand.
- Finished dose: Either local US tablet manufacturers under contract or international tablet CDMOs supplying US-labeled products through distributors.
How do DMF and Orange Book listings affect saxagliptin hydrochloride supplier eligibility?
Featured snippet answer: If you need a low-friction path for generic or follow-on product development, the practical filter is whether the API plant has an FDA DMF and whether your ANDA can leverage that DMF reference.
Orange Book does not list “suppliers”
Orange Book lists approved drug products and patents tied to those products, not the API plant operator. Supplier eligibility is therefore driven by:
- DMF submission status and cross-reference authorization
- ANDA filer’s demonstrated CMC comparability
- Site and process changes reported through supplements
DMF and regulatory mechanics buyers use
- Letter of authorization from DMF holder to applicant.
- API specification alignment to the cited DMF and ANDA.
- Inspection readiness: FDA pre-approval inspections or re-inspections tied to facility history.
What patent and exclusivity constraints affect saxagliptin product sourcing?
Featured snippet answer: Saxagliptin’s branded IP and exclusivity constraints are driven by the original NDA-related patent estate and any later formulation or method-of-use patents. These affect which parties can file and launch generics, which in turn shapes which suppliers are in active commercial qualification.
Why this matters for sourcing
- Generic launch windows influence how aggressively companies qualify new API suppliers.
- During peak launch periods, buyers lock in suppliers with shorter qualification lead times and ready DMF documentation.
What formulation dosage strengths exist for saxagliptin tablets and how does this influence supply?
Saxagliptin is marketed as oral tablets in common clinical strengths (the most widely referenced in the US market are 2.5 mg and 5 mg).
Supplier impact:
- Tablet suppliers must maintain dissolution profiles and consistent particle size distribution from API lots.
- API milling, drying, and polymorphic control can vary by manufacturer; qualification packs often include intermediate milling and blend validation.
How many qualified API suppliers are typical for saxagliptin hydrochloride?
Featured snippet answer: For a niche but still globally demanded DPP-4 inhibitor API like saxagliptin hydrochloride, it is common to see a limited set of qualified DMF-linked API suppliers, often in the low double digits across major markets, with fewer “fully interchangeable” options at the finished dosage level.
Supplier interchangeability constraints
- Different impurity profiles can trigger regulatory changes.
- Particle size and polymorphic form influence dissolution and bioequivalence.
- Residual solvents and drying profiles must match reference targets.
What generic entry risks exist if you switch saxagliptin hydrochloride API suppliers?
Featured snippet answer: Switching API suppliers can create ANDA compliance risks through changes to impurity profile, particle size distribution, polymorph, or dissolution behavior, requiring comparability work.
Practical risk points
- Impurities: even minor deviations may require supplemental analysis.
- Solid-state form: polymorph or hydrate changes can shift dissolution rates.
- Stability: degradation product patterns can change storage outcomes.
- Scale-up reproducibility: late-stage API changes can trigger additional process validation.
Which manufacturing barriers affect new entrants for saxagliptin hydrochloride API?
Featured snippet answer: The main barriers are not raw material scarcity, but process control, impurity management, and regulatory documentation tied to DMF/CMC performance.
Typical CMC barriers
- Tight impurity specs and analytical method transfer complexity.
- Chiral or stereochemical integrity control where relevant to the synthesis pathway.
- Process validation capacity for high-purity API production.
- FDA inspection readiness and consistent batch traceability systems.
Commercial landscape: how suppliers align with downstream generics
Featured snippet answer: API suppliers generally align with multiple downstream generics, with the most established producers supporting multiple ANDA applicants.
Downstream buyer behaviors
- Multi-sourcing: buyers often dual-source to manage lead time and inspection contingencies.
- Contracting: CDMOs may lock in specific API sources to avoid CMC rework.
- Documentation packs: buyers request DMF and CoA histories before qualification.
Key Takeaways
- Saxagliptin hydrochloride sourcing depends on qualified API plants with DMF-aligned CMC packages, not just generic API availability.
- Finished-dose tablet manufacturing is usually performed by separate FDA-registered sites that buy qualified API.
- Switching saxagliptin HCl suppliers can trigger ANDA comparability work tied to impurity profile, solid state, and dissolution behavior.
- Supplier eligibility is best evaluated using DMF status, CoA/spec compliance history, and site inspection readiness.
FAQs
1) What documents do generic manufacturers request from saxagliptin hydrochloride API suppliers?
Usually CoA history, DMF reference letter of authorization terms, full specifications, analytical methods/validation summaries, residual solvents and impurity profile, and stability data.
2) Does saxagliptin hydrochloride supply differ by tablet strength (2.5 mg vs 5 mg)?
Tablet strength affects formulation load and excipient ratios, so API batch performance must be consistent to keep dissolution and bioequivalence targets.
3) What is the fastest path to qualifying a new saxagliptin HCl supplier?
A DMF-backed supplier with a strong impurity/spec match and a history of producing saxagliptin HCl to equivalent specs for ANDA filings.
4) Can a supplier provide saxagliptin hydrochloride without DMF support?
Some suppliers can sell API commercially, but without DMF-linked authorization it is harder to use in an FDA-relevant pathway that relies on referenced CMC documentation.
5) What are the highest-likelihood CMC failure modes when sourcing saxagliptin HCl?
Impurity deviation, solid-state form differences, dissolution changes driven by particle size, and stability drift in degradation product patterns.
References (APA)
No sources were provided in the prompt, and no verifiable supplier list (company names, sites, DMF numbers, or FDA/Orange Book mappings) can be produced without specific citations.
